NurExone’s Exo-Top Signs Binding MOU With Made Scientific For U.S. GMP Exosome Manufacturing
(RTTNews) – NurExone Biologic Inc. (NRX.V, NRXBF) announced that its U.S. subsidiary, Exo-Top Inc has signed a binding memorandum of understanding with Made Scientific, Inc to establish an exclusive U.S. Good Manufacturing Practice manufacturing and exosome supply partnership supporting NurExone’s clinical and commercial programs.
NurExone develops exosome-based regenerative therapies, and Made Scientific is a U.S.-based cell therapy contract development and manufacturing organisation.
This collaboration combines NurExone’s bone marrow-derived exosome platform with Made Scientific’s manufacturing and regulatory expertise, creating an integrated pathway to bring exosome-based therapies from development to supply.
Under the binding MOU, Made Scientific will serve as NurExone’s exclusive U.S. partner for the manufacturing and aseptic fill-finish of NurExone’s bone marrow-derived exosomes.
Notably, the signed MOU targets initial GMP exosome batches in the first half of 2027.
NRX.V has traded between CA$0.43 and CA$1.14 over the last year. The stock closed Wednesday’s trade at CA$0.47.
For more such biotechstock news visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
